227 related articles for article (PubMed ID: 32115272)
1. Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension.
Mouratoglou SA; Patsiala A; Feloukidis C; Karvounis H; Giannakoulas G
Int J Cardiol; 2020 May; 306():187-189. PubMed ID: 32115272
[TBL] [Abstract][Full Text] [Related]
2. Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable.
El-Kersh K; Ruf KM; Smith JS
Am J Ther; 2018; 25(2):e213-e217. PubMed ID: 27003321
[TBL] [Abstract][Full Text] [Related]
3. Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.
Kimmig LM; Liao C; Bag R
Lung; 2020 Feb; 198(1):53-58. PubMed ID: 31912412
[TBL] [Abstract][Full Text] [Related]
4. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R
Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444
[TBL] [Abstract][Full Text] [Related]
5. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
6. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.
Reisbig KA; Coffman PA; Floreani AA; Bultsma CJ; Olsen KM
Ann Pharmacother; 2005 Apr; 39(4):739-43. PubMed ID: 15755791
[TBL] [Abstract][Full Text] [Related]
7. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
8. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension.
Sarangarm P; Elwood K
Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906
[TBL] [Abstract][Full Text] [Related]
9. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension.
Alkukhun L; Bair ND; Dweik RA; Tonelli AR
J Cardiovasc Pharmacol; 2014 Jan; 63(1):4-8. PubMed ID: 24084219
[TBL] [Abstract][Full Text] [Related]
11. Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study.
Wang T; Lu J; Li Q; Chen Y; Ye Q; Gao J; Yang D; Zhao L; Huang J; Zhang J
Anesth Analg; 2019 Dec; 129(6):1607-1612. PubMed ID: 31743181
[TBL] [Abstract][Full Text] [Related]
12. The role of treprostinil in the management of pulmonary hypertension.
Skoro-Sajer N; Lang I
Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
[TBL] [Abstract][Full Text] [Related]
13. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
14. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
[TBL] [Abstract][Full Text] [Related]
15. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA
J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572
[TBL] [Abstract][Full Text] [Related]
16. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.
Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM
Lancet Respir Med; 2019 Mar; 7(3):239-248. PubMed ID: 30477763
[TBL] [Abstract][Full Text] [Related]
18. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
19. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
[TBL] [Abstract][Full Text] [Related]
20. Treprostinil in the treatment of pulmonary arterial hypertension.
Feldman J; Habib N; Fann J; Radosevich JJ
Future Cardiol; 2020 Nov; 16(6):547-558. PubMed ID: 32391733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
